Concepedia

Lei Xu

LX

Statistics

Publications

92

Citations

8.8K

H-Index

36

Active since

1999

Affiliations

Merck & Co., Inc., Rahway, NJ, USA (United States)(Current)

Shanxi University of Finance and Economics

Jishou University

China Medical University

Chinese Academy of Agricultural Sciences

Lei Xu is an author at Merck & Co., Inc., Rahway, NJ, USA (United States) specializing in medicine, oncology, and life sciences.

Publications per year

1999–2025

92

Publications

92

Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study

Aurélien Marabelle, Marwan Fakih, Juanita Lopez et al. · The Lancet Oncology · 2020 · 2.5K citations · Full text

Medicine, Oncology, Pharmacotherapy +17

Efficacy and Safety of Pembrolizumab in Previously Treated Advanced Cervical Cancer: Results From the Phase II KEYNOTE-158 Study

Hyun Cheol Chung, Willeke Ros, Jean‐Pierre Delord et al. · Journal of Clinical Oncology · 2019 · 1.1K citations · Full text

Pharmacy, Oncology, Pharmacotherapy +17

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy in patients with type 2 diabetes mellitus

Itamar Raz, M Hanefeld, Lei Xu et al. · Diabetologia · 2006 · 617 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +13

Pembrolizumab in Patients With Microsatellite Instability–High Advanced Endometrial Cancer: Results From the KEYNOTE-158 Study

David M. O’Malley, Giovanni M. Bariani, Philippe A. Cassier et al. · Journal of Clinical Oncology · 2022 · 498 citations · Full text

Medicine, Oncology, Gynecologic Oncology +10

Pembrolizumab in microsatellite instability high or mismatch repair deficient cancers: updated analysis from the phase II KEYNOTE-158 study

Michele Maio, Paolo A. Ascierto, L. V. Manzyuk et al. · Annals of Oncology · 2022 · 445 citations · Full text

Life Sciences, Oncology, Immunotherapy +13

1–5 of 92